Skip to main content

Combigan FDA Approval History

FDA Approved: Yes (First approved October 30, 2007)
Brand name: Combigan
Generic name: brimonidine tartrate and timolol maleate
Dosage form: Ophthalmic Solution
Company: Allergan plc
Treatment for: Intraocular Hypertension, Glaucoma

Combigan (brimonidine tartrate and timolol maleate) is an alpha adrenergic receptor agonist and beta adrenergic receptor inhibitor combination ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with glaucoma or ocular hypertension who require adjunctive or replacement therapy due to inadequately controlled IOP.

Development timeline for Combigan

DateArticle
Oct 31, 2007Approval Allergan, Inc. Receives FDA Approval for Combigan (brimonidine tartrate/timolol maleate ophthalmic solution) 0.2%/0.5%
Dec 21, 2006Allergan Announces FDA Issues Approvable Letter for Combigan 0.2%/0.5%

See also

Combigan (brimonidine tartrate and timolol maleate) Consumer information

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Medical Disclaimer